Methylnaltrexone: the answer to opioid-induced constipation?

Area of Science:

• Gastroenterology
• Pharmacology
• Oncology

Background:

• Opioid-induced constipation (OIC) is a prevalent and distressing side effect in patients using opioids for pain management, particularly in palliative care, chronic pain, and post-operative settings.
• Existing treatments for OIC often lack efficacy or are associated with significant adverse effects, necessitating novel therapeutic approaches.

Purpose of the Study:

• To evaluate methylnaltrexone as a targeted treatment for opioid-induced constipation.
• To highlight methylnaltrexone's mechanism of action and its potential to improve patient quality of life.

Main Methods:

• Review of methylnaltrexone's pharmacological properties, including its role as a peripherally acting mu-opioid receptor antagonist.
• Discussion of clinical data supporting the efficacy and safety of methylnaltrexone for OIC.

Main Results:

• Methylnaltrexone selectively antagonizes peripheral gastrointestinal opioid receptors, alleviating OIC without interfering with central analgesia.
• The subcutaneous formulation of methylnaltrexone has received FDA approval for OIC treatment.

Conclusions:

• Methylnaltrexone represents a significant advancement in managing OIC, offering a targeted and effective therapeutic option.
• Further investigation into intravenous and oral formulations of methylnaltrexone is ongoing to expand treatment accessibility.